Ubs Asset Management Americas Inc Ultragenyx Pharmaceutical Inc. Transaction History

Ubs Asset Management Americas Inc

  • $379 Billion
  • Q1 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 232,360 shares of RARE stock, worth $8.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
232,360
Previous 202,376 14.82%
Holding current value
$8.4 Million
Previous $8.51 Million 1.17%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 19, 2025
BUY
$36.21 - $45.78 $1.09 Million - $1.37 Million
29,984 Added 14.82%
232,360 $8.41 Million
Q4 2024

Feb 14, 2025
BUY
$42.07 - $57.72 $1.04 Million - $1.42 Million
24,620 Added 13.85%
202,376 $8.51 Million
Q3 2024

Nov 14, 2024
BUY
$40.21 - $59.36 $38,078 - $56,213
947 Added 0.54%
177,756 $9.87 Million
Q2 2024

Aug 13, 2024
BUY
$37.42 - $51.61 $1.74 Million - $2.4 Million
46,549 Added 35.74%
176,809 $7.27 Million
Q1 2024

May 15, 2024
BUY
$43.02 - $53.69 $518,563 - $647,179
12,054 Added 10.2%
130,260 $6.08 Million
Q4 2023

Feb 14, 2024
BUY
$31.73 - $49.19 $116,925 - $181,265
3,685 Added 3.22%
118,206 $5.65 Million
Q3 2023

Nov 13, 2023
BUY
$34.92 - $46.66 $298,705 - $399,129
8,554 Added 8.07%
114,521 $4.08 Million
Q1 2023

May 15, 2023
SELL
$36.99 - $48.71 $590,064 - $777,021
-15,952 Reduced 13.08%
105,967 $4.25 Million
Q4 2022

Feb 14, 2023
BUY
$33.72 - $46.33 $785,069 - $1.08 Million
23,282 Added 23.6%
121,919 $5.65 Million
Q3 2022

Nov 14, 2022
SELL
$39.96 - $66.14 $640,918 - $1.06 Million
-16,039 Reduced 13.99%
98,637 $4.08 Million
Q2 2022

Aug 12, 2022
SELL
$45.8 - $85.4 $23,220 - $43,297
-507 Reduced 0.44%
114,676 $6.84 Million
Q1 2022

May 16, 2022
BUY
$62.2 - $84.4 $725,811 - $984,863
11,669 Added 11.27%
115,183 $8.36 Million
Q4 2021

Feb 14, 2022
BUY
$73.71 - $87.86 $796,141 - $948,975
10,801 Added 11.65%
103,514 $8.7 Million
Q3 2021

Nov 15, 2021
SELL
$77.92 - $102.4 $199,319 - $261,939
-2,558 Reduced 2.68%
92,713 $8.36 Million
Q2 2021

Aug 16, 2021
BUY
$92.19 - $115.71 $2.1 Million - $2.63 Million
22,754 Added 31.38%
95,271 $9.08 Million
Q1 2021

May 14, 2021
BUY
$106.9 - $167.73 $440,000 - $690,376
4,116 Added 6.02%
72,517 $8.26 Million
Q4 2020

Mar 01, 2021
BUY
$84.4 - $177.39 $258,770 - $543,877
3,066 Added 4.69%
68,401 $9.47 Million
Q3 2020

Nov 13, 2020
BUY
$72.98 - $90.0 $382,196 - $471,330
5,237 Added 8.71%
65,335 $5.37 Million
Q2 2020

Aug 14, 2020
SELL
$46.91 - $78.22 $14,542 - $24,248
-310 Reduced 0.51%
60,098 $4.7 Million
Q1 2020

May 15, 2020
BUY
$33.8 - $62.9 $33,394 - $62,145
988 Added 1.66%
60,408 $2.68 Million
Q4 2019

Feb 14, 2020
BUY
$36.08 - $45.83 $48,202 - $61,228
1,336 Added 2.3%
59,420 $2.54 Million
Q3 2019

Nov 14, 2019
BUY
$42.5 - $63.11 $414,120 - $614,943
9,744 Added 20.16%
58,084 $2.48 Million
Q2 2019

Aug 15, 2019
BUY
$54.93 - $74.36 $251,414 - $340,345
4,577 Added 10.46%
48,340 $0
Q1 2019

May 14, 2019
BUY
$39.87 - $69.36 $331,479 - $576,659
8,314 Added 23.45%
43,763 $0
Q4 2018

Feb 13, 2019
BUY
$38.89 - $77.3 $65,179 - $129,554
1,676 Added 4.96%
35,449 $1.54 Million
Q3 2018

Nov 14, 2018
BUY
$71.81 - $90.15 $43,301 - $54,360
603 Added 1.82%
33,773 $0
Q2 2018

Aug 14, 2018
SELL
$48.54 - $85.31 $12,620 - $22,180
-260 Reduced 0.78%
33,170 $0
Q1 2018

May 14, 2018
BUY
$44.33 - $58.52 $300,025 - $396,063
6,768 Added 25.38%
33,430 $0
Q4 2017

Feb 09, 2018
BUY
$43.54 - $57.32 $71,231 - $93,775
1,636 Added 6.54%
26,662 $0
Q3 2017

Nov 13, 2017
BUY
$49.79 - $66.32 $1.25 Million - $1.66 Million
25,026
25,026 $0

Others Institutions Holding RARE

# of Institutions
336
Shares Held
88.9M
Call Options Held
1.08M
Put Options Held
1.04M
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.53B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email